Scotland
Digital therapeutics world first for Big Health in Scotland
Dominic Tyer
anxiety, Big Health, digital health, digital therapeutics, insomnia, NHS, Scotland
0 Comment
Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
Collaborate to simplify cancer trials and accelerate post-pandemic recovery
Scotland backs Bavencio for bladder cancer after NICE says no
Phil Taylor
Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer, Scotland, Scottish Medicines Consortium, urothelial carcinoma
0 Comment
Scotland backs rare blood cancer drug Poteligeo rejected by NICE
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Calquence, Eli Lilly, Kyowa Kirin, NHS, nintedanib, Olumiant, Oncology, Poteligeo, Scotland, Scottish Medicines Consortium, Servier
0 Comment
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS
Phil Taylor
Alexion, AstraZeneca, Health Technology Assessment, HEOR, nephrology, NHS, rare disease, Scotland, Soliris, Ultomiris
0 Comment
Scotland opens door to Translarna for Duchenne muscular dystrophy
Phil Taylor
asthma, Duchenne muscular dystrophy, Dupixent, HEOR, PTC Therapeutics, rare disease, Regeneron, Sanofi, Scotland, Translarna
0 Comment
Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensma
Phil Taylor
HEOR, NHS, Novartis, Roche, Rozlytrek, Scotland, Scottish Medicines Consortium, Zolgensma
0 Comment
Market Access/ Views & Analysis/ Views and analysis
How does HTA for orphan drugs differ across Europe?
George Underwood
England, Europe, France, Germany, HTA, NICE, orphan drugs, Rare diseases, Scotland, SMC, UK
0 Comment